Avidity Biosciences, Inc.

Avidity has further strengthened the case for its Duchenne muscular dystrophy candidate, delpacibart zotadirsen, with Phase I/II data showing it boosted levels of the missing dystrophin muscle protein

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Avidity Biosciences could be about to transform treatment of three muscular dystrophy diseases with first-in-class RNA-based therapies, the most advanced being on track for filing by the end of 2025.

With a US Food and Drug Administration partial clinical hold lifted, Avidity Biosciences, Inc. is moving forward with a Phase III trial of its antibody-oligonucleotide conjugate (AOC) candidate delp